HH-006 by Huahui Health for Hepatitis D: Likelihood of Approval

HH-006 is under clinical development by Huahui Health and currently in Phase I for Hepatitis D.

Intranasal vaccine shows promise against COVID variants in hamsters

Intranasal mRNA-LNP vaccines show promise in Syrian golden hamsters, effectively reducing SARS-CoV-2 viral loads and lung pathology. The study suggests potential efficacy against new variants,

September 26, 2023

Senate grills pharma CEOs, who emerge from hearing on drug prices largely unscathed

For about three hours on Thursday, senators pressed the CEOs of Merck, Bristol Myers Squibb and Johnson & Johnson on why US drugs cost so

February 9, 2024

Researchers explore immunomodulating targets for improving glioblastoma therapies

Researchers have delved into the intricate heterogeneity of glioblastoma, a notoriously aggressive brain tumor, using advanced single-cell RNA sequencing and innovative zebrafish avatars. Their findings

October 8, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.